Pyrilutamide (development code KX-826) is a nonsteroidal anti-androgen drug that prevents testosterone and dihydrotestosterone from binding to the androgen receptor in hair follicles. It is being developed by Kintor Pharmaceuticals for androgenic alopecia and acne in China and the United States.
This topical pyrilutamide appears to have an impressive mechanism of action, but its effectiveness in hair loss needs to be confirmed by further clinical trials. For further details, buy GlobalData’s Pyrilutamide PTSR and LoA report.
Dosage
Buy pyrilutamide is a topical androgen receptor antagonist that can prevent hair loss. It works by blocking testosterone and DHT from binding with the androgen receptor in hair follicles. It has shown promise in clinical trials and has been compared to finasteride. It also has less side effects than oral 5-alpha reductase inhibitors, such as lowered libido and erectile dysfunction.
The drug has been developed by Kintor Pharmaceuticals, which is focused on developing small molecule therapeutics. It has a number of clinical development programs, including GT20029 and pyrilutamide. It is currently in phase II for androgenic alopecia.
The pyrilutamide solution contains 0.5% of the compound in a propylene glycol and ethanol vehicle. The raw material pyrilutamide used in this product was confirmed to be >99% pure by a professional lab. The solution is shipped in a 30ml bottle and comes with a calibrated dropper. The solution can be stored at -20 °C for 1 year. It is for laboratory developmental research USE ONLY.
Side effects
Pyrilutamide is a nonsteroidal antiandrogen that works as an androgen receptor antagonist. It inhibits the binding of androgens to androgen receptors in the scalp, which reduces the number of hair follicles that produce androgens. As a result, it prevents the progression of androgenetic alopecia in men.
The drug is being developed by Kintor Pharmaceutical for the treatment of male and female androgenetic alopecia (pattern hair loss). It has completed phase 2 clinical trials in China and the US, and is expected to enter phase 3 trials in 2021.
In contrast to other hair loss treatments, buy pyrilutamide from MV Supplements is not associated with severe side effects. In addition, the topical formulation has a low systemic exposure of the drug, making it safe for daily use. The purity of the raw material used to manufacture pyrilutamide has been confirmed to be >99% by a third-party laboratory. Each batch of pyriPure is tested for purity before shipment. PyriPure is shipped in a 70% ethanol / 30% propylene glycol solution, and comes with a calibrated dropper for accurate dosing.
Precautions
Pyrilutamide (development code KX-826) is a nonsteroidal antiandrogen and a selective high-affinity silent antagonist of the androgen receptor. It is being developed by Kintor Pharmaceutical for androgenic alopecia and acne. The drug has completed phase II clinical trials in China and the United States.
Compared to finasteride and RU 58841, pyrilutamide looks like a promising new addition to the hair loss arsenal. It appears to have similar side effects, and it may be effective for both men and women. It also works through a different mechanism than the two other drugs.
Its phase 2 trial has been completed and the results are expected to be released by the end of 2021. This will be an important step in the development of this compound. The results will determine whether it is safe and effective in treating alopecia. This is a very serious condition that affects millions of people. It is a very complex disease and requires careful management.
Warnings
Pyrilutamide is a new topical drug that works by inhibiting DHT production in the hair follicles. It’s been shown to be effective in clinical trials for male pattern baldness. It also doesn’t cause side effects like decreased libido and erectile dysfunction, which are common with oral 5-alpha reductase inhibitors such as finasteride and dutasteride.
The company has recently completed phase-2 trials for androgenetic alopecia in China and is expected to complete the US phase 3 trial next year (2021). We’re hoping that this new treatment will offer some hope for people who can’t use finasteride or RU 58841 due to negative side effects.
Kintor Pharmaceuticals is a clinical stage drug company focused on discovering medicine and drugs for novel diseases. Its current pipeline includes Proxalutamide (GT0918), Pyrilutamide (KX826), ALK-1 (GT009001), Destorsertib (GT0486F) and GT20029. It carries out research and development operations to discover therapeutic treatments for diseases such as metastatic castration resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, and leukaemia.
